6:35 PM
 | 
May 01, 2013
 |  BC Extra  |  Financial News

Novo's CV outcomes trial to start 'within a year'

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) disclosed in its 1Q13 earnings on Wednesday that it plans to start "within a year" the FDA-requested CV outcomes trial of Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart. In a February complete response letter for the diabetes products,...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >